LOS ANGELES — Startup Omeat has emerged from stealth mode and is preparing to enter the cultivated meat market. The company claims it has a new method that will reduce input costs and provide scalability to the nascent category.

The process uses animal plasma as the source of its growth media. The media may be used to cost-effectively grow any kind of meat, such as beef, pork, chicken or fish, according to the company. Omeat initially is focusing on beef due, in part, to research from the Good Food Institute that shows ground beef is the cultivated meat consumers have expressed the most interest.

“We saw an opportunity to leverage our expertise to discover a scalable way to grow cultivated meat,” said Ali Khademhosseini, founder and chief executive officer. “The approach we uncovered and are currently scaling is a simple and elegant solution that taps into the natural biology of animals to let nature do its work.”

Omeat raised an oversubscribed $40 million Series A funding in 2022. Investors include S2G Ventures, Google Ventures, Bold Capital Partners, Tyson Ventures, the venture capital arm of Tyson Foods Inc., Rethink Food, Trailhead Capital and Cavallo Ventures.

The company is currently building a pilot plant and expanding its staff to prepare for commercialization. Omeat also is working with the Food and Drug Administration and the US Department of Agriculture to gain regulatory approval. Upside Foods and GOOD Meat, the cultivated meat arm of Eat Just Inc., both received approval on June 21 from the USDA to start selling cultivated meat in the United States.